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Hansen M, Couppe C, Hansen CS, Skovgaard D, Kovanen V,
Larsen JO, Aagaard P, Magnusson SP, Kjaer M. Impact of oral
contraceptive use and menstrual phases on patellar tendon morphol-
ogy, biochemical composition, and biomechanical properties in fe-
male athletes. J Appl Physiol 114: 998–1008, 2013. First published
February 21, 2013; doi:10.1152/japplphysiol.01255.2012.—Sex dif-
ferences exist with regards to ligament and tendon injuries. Lower
collagen synthesis has been observed in exercising women vs. men,
and in users of oral contraceptives (OC) vs. nonusers, but it is
unknown if OC will influence tendon biomechanics of women under-
going regular training. Thirty female athletes (handball players,
18–30 yr) were recruited: 15 long-term users of OC (7.0 0.6 yr) and
15 nonusers (5 yr). Synchronized values of patellar tendon elonga-
tion (obtained by ultrasonography) and tendon force were sampled
during ramped isometric knee extensor maximum voluntary contrac-
tion to estimate mechanical tendon properties. Furthermore, tendon
cross-sectional area and length were measured from MRI images, and
tendon biopsies were obtained for analysis of tendon fibril character-
istics and collagen cross-linking. Overall, no difference in tendon
biomechanical properties, tendon fibril characteristics, or collagen
cross-linking was observed between the OC users and nonusers, or
between the different phases of the menstrual cycle. In athletes,
tendon cross-sectional area in the preferred jumping leg tended to be
larger than that in the contralateral leg (P  0.09), and a greater
absolute (P  0.01) and normalized tendon stiffness (P  0.02), as
well as a lower strain (P  0.04), were observed in the jumping leg
compared with the contralateral leg. The results indicate that long-
term OC use or menstrual phases does not influence structure or
mechanical properties of the patellar tendon in female team handball
athletes.
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COMPARED WITH THEIR MALE counterparts, women display a greater
risk of knee anterior cruciate ligament (ACL) tearing (2, 3, 31),
but there is no monofactorial explanation for this connective tissue
sex disparity. In addition to anatomical and neuromuscular expla-
nations (32), sex differences in hormonal levels may be important.
This notion is based on the fact that estrogen receptors have been
identified in the human ACL (19, 43, 67), and women who are
chronically exposed to high levels of estrogen, i.e., users of oral
contraceptives (OC), may have altered collagen content of ten-
dons and ligaments (27), which may change the biomechanical
properties. In support of an acute effect of estrogen on connective
tissue, the risk of ACL injury has been found to be higher in the
preovulatory phase of the menstrual cycle (73), when circulating
estrogen is peaking. Likewise, a greater joint laxity has been
observed during the ovulation phase of the menstrual cycle (16,
33, 58, 62, 70), although there are contradictory result as well (5,
8, 10, 11, 61, 77).
Use of OC suppresses endogenous secretion of female hor-
mones and thereby the naturally occurring cyclic hormonal vari-
ations. Use of OC has been associated with a greater risk of
Achilles tendinopathy (37), persistent pelvic pain, pelvic joint
instability (66), and lower back pain (76, 82), whereas others have
reported a lower risk of traumatic injuries (55) or no difference in
the risk of lower back pain (9) and ACL injuries (1, 63) compared
with non-OC (NOC) users. The knowledge about the effect of OC
on tendon and ligament biomechanical properties is sparse. Bryant
et al. (8) observed a reduced strain of the triceps surae aponeurosis
during maximal isometric plantar flexion in OC users, and Mar-
tineau et al. (51) showed a lower passive anterior translation of the
tibia as measured by KT1000 in OC users compared with NOC.
However, there appears to be no effect of OC on passive periph-
eral joint laxity (60).
Endogenous or exogenous estrogen may influence the risk of
injuries by changing the structural composition of ligaments
and tendons and thereby introduces changes in tendon mechan-
ical properties. Nevertheless, equivocal data exist in the liter-
ature. Animal studies have reported no effect of estrogen on the
mechanical properties of sheep knee ligaments (75), whereas
ACL from rabbits ruptures at lower stress loads after 30 days
of estrogen administration (74). In contrast, administration of
synthetic estradiol and progesterone (ethinyl estradiol and
levonorgestrel) as in OC strengthen the ACL in rats within 12
hormonal cycles (81). Human data have shown a lower nor-
malized tendon stiffness (Young’s modulus) in ovariectomized
women using estrogen replacement therapy (ERT) compared
with postmenopausal controls (25). In the latter study, tendon
collagen fractional synthesis rate and the density of small-
diameter tendon fibrils were higher in ERT users, which
indicate that estrogen may enhance tendon collagen turnover.
In contrast, tendon collagen fractional synthesis rate is reduced
in young OC users compared with controls (27). Similar to the
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animal findings, this indicates a differential effect between
estrogen (estradiol) and synthetic estrogen (ethinyl estradiol).
A lower tendon collagen synthesis rate and overall lower
tendon collagen turnover may enhance the possibility for
introducing intra- and intermolecular collagen cross-links and
thereby increase tendon stiffness and resistance against rup-
tures. However, in perspective to the risk of sports injuries, it
is interesting to note that both in vitro (41, 42) and in vivo
observations (26) indicate a negative interaction between me-
chanical tendon loading and estrogen (estrogen or OC) abun-
dance on collagen synthesis.
Our aim was to test mechanical properties of the patellar tendon
in NOC and OC users at two different time points during the
menstrual cycle and pill cycle, respectively. In addition to assess-
ing in vivo tendon biomechanical properties, a patellar tendon
biopsy was obtained from each participant for histological and
biochemical analyses of the tendon structure to link cellular
tendon properties to the overall biomechanical properties of the
patella tendon in vivo.
MATERIALS AND METHODS
Design
The project was designed as a cross-sectional study comparing
female athletes (handball players), who were either chronic OC users
or NOC. The experiment consisted of a screening protocol followed
by the experimental day, which was planned in the OC users in either
week 3 of the pill cycle or the nonpill week and in the NOC in the
menstrual phase or in the 1–3 days after the day of a positive ovulation
test. On the experimental day, the biomechanical properties of the
patellar tendon in each leg were assessed during a ramped maximal
voluntary isometric contraction (13, 14). Afterwards, tendon biopsies
were obtained from the patellar tendons, which were analyzed for
cross-links and collagen concentration and used for fibril character-
ization (29, 38). The study complied with the Declaration of Helsinki
and was approved by the local ethics committees in Copenhagen
(H-C-2009-025). All subjects gave their informed consent to partici-
pate before the experiments.
Subjects
Subelite female handball players (18–30 yr) were recruited from 12
local handball clubs in Copenhagen. Female Team handball athletes
were recruited since they are known to chronically load their tendons
and ligaments, and they participate in a sport where ligament and
tendon injuries are frequent (6, 56, 57). The subjects were nonsmok-
ers, nulliparous, on no medication (except OC in the OC users), and
absent of any orthopedic and medical conditions, as judged by history
and routine medical examination. Women with a cycle length outside
the typical range of 21–35 days were excluded (17). Additional
exclusion criteria were parental predisposition for diabetes, connec-
tive tissue diseases, previous or present pregnancy, and use of an
intrauterine device with hormones or use of minipills.
Fifteen OC users were included. They had used OC for a duration of
7 1 yr (range 3–10 yr). They used different types of OC containing four
different kinds of synthetic progesterone and different amount of ethinyl
estradiol: 1) 30 g ethinyl estradiol and 0.15 mg levonorgestrel (n  1);
2) 20 or 30 g ethinyl estradiol and 0.075 mg gestoden (n 5); 3) 20 or
30 g ethinyl estradiol and 0.15 mg desogestrel (n  6); and 4) 30 g
ethinyl estradiol and 3 mg drospirenon (n  3). Seven of the OC users
were tested in the last week of the 3-wk pill period (days 15–21), and the
remaining eight OC users were tested in the off-pill week (days 2–5).
As a control group, 15 NOC users participated. None of them had
used OC for at least 5 yr (2 mo in total). They were tested in either
the follicular phase (FP, n  7, days 1–6 of menstrual cycle) or the
luteal phase (LP) of the menstrual cycle (NOC LP, n  8, days 1–4
after a positive ovulation urine test; Wondfo One step ovulation urine
test, Guangzhou Wondfo Biotechnology, Guangzhou, China). Blood
samples analyzed for estradiol, progesterone, follicular stimulating
hormone (FSH) and luteinizing hormone (LH) were used to confirm
the menstrual phases.
Screening
All participants visited the laboratory at least 1 wk before the
experimental day to receive detailed information about the experiment
and went through a health examination and blood sampling. The blood
samples were analyzed for plasma C-reactive protein, plasma creatine
kinase, plasma calcium, plasma creatinine, plasma alkaline phospha-
tase, and hemoglobin A1c (HbA1c) (%). All results were within the
normal range within the included women. Moreover, the two groups
were similar with regard to age, height, weight, body mass index, and
body composition, as measured by the sum of four skinfold measure-
ments (18) (Table 1).
A criterion for participation was physical training at least three
times a week. The OC users had been training and playing handball
regularly for, on average, 13 ys (range 6–19 yr), which was compa-
rable to NOC users (average 12 yr, range 4–22 yr). Similarly, no
significant difference in training status between OC and NOC was
observed (Table 1). Training status was tested in two different ways:
1) daily physical activity level determined by use of a validated
questionnaire (1); and 2) maximal oxygen uptake (V˙ O2 max) per
kilogram body weight per minute determined in an incremental
treadmill test (Table 1). Protocol for the V˙ O2 max test is as follows.
After 5-min warm-up, the subjects were running for 2 min before the
slope of the treadmill was raised 2%. Thereafter, the slope of the
treadmill was raised 2% each 90 s until voluntary exhaustion. Respi-
ratory variables (averaged for each 15-s period) were measured
continuously through a mouthpiece connected to an automated met-
abolic cart (AMIS 2001, Innovision, Odense, Denmark). The mean of
the three highest 15-s values was recorded as V˙ O2 max. Heart rate (HR)
was measured continuously by a wireless HR monitor (Polar Sport
Tester, Polar Electro OY, Kempele, Finland). To ensure that a true
V˙ O2 max was attained, at least two of the following three criteria had
to be fulfilled: 1) a V˙ O2 max plateau was reached; 2) a HR was within
5 beats/min of the age-adjusted maximal HR; and 3) CO2 produc-
tion (l/min)/O2 uptake (l/min)  1.1.
Patellar Tendon Cross-Sectional Area and Length
Patellar tendon cross-sectional area (CSA) and length were deter-
mined using magnetic resonance imaging (MRI), as previously de-
scribed (39). MRI was performed before the biomechanical test and
biopsy procedure. Patellar tendon CSA was measured 1) just distal to
the patellar insertion; 2) just proximal to the tibia insertion; and
3) midway between the two sites (39). The patellar tendon length was
Table 1. Subject characteristics
NOC OC
Age, yr 22  1 23  1
Height, m 1.70  0.02 1.69  0.02
Weight, kg 69  3 68  2
BMI, kg/m2 24  1 23  1
Body fat, % 29  1 32  1
Fitness level, O2 ml  min1  kg1 46  1 45  1
V˙ O2max, O2 l/min 3.2  0.1 3.0  0.1
Physical activity level (MET/24t) 1.9  0.1 1.8  0.1
Use of OC, yr 0  0 7.0  0.6
Values are means  SE; n  15 (NOC), n  15 (OC users). BMI, body
mass index; V˙ O2max, maximal oxidative uptake of oxygen; MET, metabolic
equivalents; OC, oral contraceptives; NOC, nonusers of oral contraceptives.
No significant differences between groups except for duration of OC use.
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obtained by measuring the distance from the dorsal insertion at the
patella apex to the dorsal insertion on the tibia (39). The patellar
tendon CSA and patellar tendon length were manually outlined using
the software program Osiris 4.19 (http://www.softpedia.com). Tendon
CSA and length were measured using gray-scale image display. The
mean value of three measurements of the same image was used for
analysis of the Patellar tendon CSA at each anatomical position. An
average of the proximal, midway, and distal images was used for the
calculation of normalized biomechanical properties. The MRI assess-
ment investigator was blinded with regards to subject grouping.
Intraindividual coefficient of variation (CV%) during the three mea-
surements of each specific site was 1.3%. To compare tendon dimen-
sions between subjects of various body size, tendon CSA data were
normalized to body weight and raised to the power of two-thirds (49).
Mechanical Properties of the Patellar Tendon
Details of the measurement, including the reliability of the method
in our laboratory, have been reported previously (28). Within-day
correlation coefficient and typical error percent results for repeated
measures were 0.95 and 9.9% for tendon stiffness, 0.97 and 5.5% for
tendon strain, and 0.94 and 9.4% for Young’s modulus. Subjects
performed a 5-min warm-up on a stationary bike to secure proper
preconditioning of the tendon before testing. Subsequently, the sub-
jects were seated in a custom-made rigid chair with both hips and
knees flexed to an angle of 90°. A leg cuff, which was connected to
a strain gauge (Bofors KRG-4, Bofors, Sweden) through a rigid steel
rod perpendicular to the lower leg, was mounted on the leg just above
the medial malleolus. An ultrasound probe (7.5 MHz, linear array
B-mode; Sonoline Sienna, Siemens, Erlangen, Germany) was fitted
into a custom-made rigid cast that was secured to the skin above the
patellar tendon in the sagittal plane. The ultrasound probe and cast
were positioned so that the distal patella, the entire patellar tendon,
and the proximal tibia were all visible within the viewing field
throughout the isometric ramped contractions performed.
Ultrasound S-VHS video images obtained during the ramp trials
were sampled at 50 Hz on a personal computer using frame-by-frame
capturing software (Matrox Marvel G400-TV, Dorval, Quebec, Can-
ada) (14). Force was sampled on two separate personal computers at
50 Hz via a 12-bit analog-to-digital converter (dt2810A; Data Trans-
lation). The two computers were interconnected to permit synchro-
nous sampling of all data using a custom-built trigger device (7). The
subjects performed four to five slow isometric knee extensions ramps
by applying gradually increasing force until maximum over a 10-s
period during which patellar tendon displacement and knee extension
force were measured simultaneously. Each ramp was separated by a
2-min rest period. All measurements were performed on one side,
randomized to either the right or left knee. During the ramp contrac-
tions, force was sampled at 50 Hz and subsequently digitally low-pass
filtered (1.0-Hz cutoff frequency) using a fourth-order zero-lag But-
terworth filter (14).
Tendon force was calculated by dividing the measured knee exten-
sion moment by the internal moment arm, the latter estimated from
individually measured femur lengths (78). Tendon stress was calcu-
lated by dividing tendon force with the average patellar tendon CSA
determined at the three length levels (proximal, mid, and distal) by
MRI. Tendon deformation was defined as the change in distance
between the patellar apex and the tibia (28, 46). Tendon strain was
calculated as the change in length normalized to resting tendon length.
Each single force-deformation curve was fitted to a second- or
third-order polynomial fit (r2 0.98). Tendon stiffness [change () in
force/deformation] and Young’s modulus (stress/strain) based on
largest common force was calculated in the final 20% of the force-
deformation and stress-strain curves, respectively (46). Mechanical
properties of the patellar tendon were analyzed both at the same
common force (2,500 N) for both groups (group common force) and
at the maximal individual common force (comparing the two legs in
each subject) to take into account nonsignificant differences in abso-
lute and normalized force between the groups and the legs.
Tendon Biopsies
Tendon biopsies were obtained randomly from either the jumping
leg or contralateral leg, according to procedures described in detail
elsewhere (29, 38). In brief, after sterilization of the insertion site, the
skin was injected with local anesthetic (1% lidocaine), and a 3- to
5-mm-long incision was made distally to the patella apex. Tendon
biopsies were obtained by using a 16-G Monopty biopsy instrument
(Bard, Covington, GA) with a disposable core biopsy needle (14
gauge). The biopsy needle was inserted into the tendon surface at an
30° angle and fired, securing a tissue sample of approximately 8–10
mg. Biopsies were cleared of external adipose tissue and blood. The
piece used for analysis of collagen cross-links was snap-frozen in
liquid nitrogen and stored at 80°C for subsequent analysis. The
other part of the tendon biopsy was used for transmission electron
microscopy (TEM). The biopsy specimens for TEM were fixed in a
2% gluteraldehyde in 0.05 M sodium phosphate buffer (pH 7.2) and
stored at 4°C until subsequent tissue processing. The procedure for
TEM and the following measurements of collagen fibril diameter have
previously been described in details (48).
Biochemical analysis of collagen cross-links. Freeze-dried tendon
samples were hydrolyzed in 6 M HCl (	108°C, 24 h) and evaporated
into dryness and dissolved in H2O. Hydroxyproline, the collagen-
specific amino acid, was measured spectrophotometrically to quantify
collagen protein (15). Hydroxylysyl pyridinoline (HP), lysyl pyridino-
line (LyP), and pentosidine were analyzed via a single reversed-phase
high-performance liquid chromatography (HPLC) run and detected on
the basis of their natural fluorescence (4). At 0–16 min, the wave-
length for HP and LyP fluorescence was 400 nm for emission and 295
nm for excitation. The wavelengths were changed at 16–60 min to
328/378 nm to measure pentosidine. For the elution of the cross-links,
a gradient was built up to contain 17% eluent B (75% acetonitrile with
0.13% heptafluorobutyric anhydride) at 0 min and 25% eluent B at 30
min. Eluent A was 0.13% heptafluorobutyric anhydride. Flow rate was
1 ml/min. HP was eluted at 12 min, LyP at 13.5 min, and pentosidine
at 23 min. The HPLC system used included Quaternary Gradient
Pump unit, PU-2089 Plus, Intelligent AutosamplerAS-2057 Plus, and
Intelligent Fluorescence Detector FP-2020 by Jasco. Data processing
software was Jasco Chrompass. The LiChroCART 125–4 column was
from Merck Hitachi. The HP, LyP, and pentosidine concentrations
were calculated according to the external standard method using pure
HP, LyP, and pentosidine compounds at four different concentrations
in each HPLC run. The intra-assay CV% based on duplicates within
a run was 2.6, 3.7, and 3.9% for HP, LyP, and pentosidine, respec-
tively. The detection limit for HP and LyP is 0.4 pmol and 0.05 pmol
for pentosidine.
Stereology. A simple, random sample of 10 digitized electron micros-
copy images were obtained from each biopsy cross section to obtain an
estimation of the volume fraction of collagen fibrils and their density
(number per CSA) and size distribution (diameter). The analyses were
carried out on a computer monitor onto which the digitized electron
microscopy image was merged with a graphic representation of the
stereological test systems (C.A.S.T.-grid software, The International
Stereology Center at Olympus). Each TEM image was examined with 16
uniformly positioned points (for estimation of the volume faction) and 16
uniformly positioned unbiased counting frames (23) for estimation of the
density of fibrils and to obtain a number-weighted sample of fibrils for
measuring the diameter distribution. Each counting frame had an area of
0.0426 m2 and was positioned in a fixed position relative to the image.
The counting frames covered 15% of the area of the TEM images. On
average, 446  42 fibrils (range 303–865) were analyzed per biopsy
cross section in the NOC specimens, and 384 25 from each of the OC
specimens (range 270–514). All measurements were performed in a
blinded fashion.
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Blood Analyses
All blood samples were taken from an antecubital vein. Serum
estradiol was determined by chemiluminescent competitive immuno-
assay (estradiol, Diagnostic Product, Los Angeles, CA). Plasma pro-
gesterone was determined by a microparticle enzyme immunoassay
(progesterone, Abbott Diagnostics, Wiesbaden, Germany). Testoster-
one was analyzed by liquid chromatography mass spectrometry using
an atmospheric pressure chemical ionization interface (CV%  15%)
at Statens Serum Institute, Denmark. Serum LH and FSH were
determined by an electrochemiluminescent immunoassay at Hvidovre
Hospital, Denmark. Blood glycated HbA1c was determined by ion
exchange HPLC at Bispebjerg Hospital. Insulin-like growth factor I
(IGF-I) was determined by time-resolved immunofluorometric assays
after acid-ethanol extraction, as previously described (21). Relaxin
was determined by an enzyme-linked-immunosorbent assay (ALPCO
Diagnostics, Salem, MA). For each variable, all samples were mea-
sured in the same assay run (intra-assay CV%  5%).
Statistical Analysis
Statistical analyses for differences between OC and NOC in subject
characteristics (Table 1), fibril characteristics (see Table 5) and tendon
content of collagen and cross-links (Fig. 3) were performed using
Student’s unpaired t-tests. One-way ANOVA was used to test for
differences between groups (NOC FP, NOC LP, OC pill period, and
OC off-pill period) in serum estradiol, testosterone, FSH, and IGF-I
and HbA1c since these data passed normality criterions (Shapiro-
Wilk). Post hoc tests were performed when statistical significance was
observed (all pairwise multiple comparison procedures, Holm-Sidak
method). Data for progesterone, LH, and relaxin did not follow a
normal (Gaussian) distribution, and Mann-Whitney rank sum tests,
therefore, were performed to test for differences between groups. A
two-way ANOVA (one-factor repetition: jumping leg vs. contralateral
leg) was used to test for difference in tendon CSA and tendon
biomechanical properties caused by training load or use of OC.
Pearson product-moment correlation analyses were performed to test
for correlation between blood parameters and tendon biomechanical
properties (individual common force data) and between HbA1c and
tendon cross-links (HP, LyP, and pentosidine). The level of signifi-
cance was set at P  0.05. The statistical analyses were performed
using the statistical software package Sigma Plot version 11.0.
RESULTS
Blood Parameters
The concentrations of 17
-estradiol and progesterone were
higher in the NOC group tested in the days after ovulation (NOC
LP) compared with both OC users and the NOC group tested in
the days after start of menstruation (NOC FP). Estradiol was
below the detection level (0.1 nmol/l) in five of seven OC users in
the pill period and three of the eight OC users in the off-pill
period. IGF-I was lower in the OC group tested in the pill period
compared with the other groups. No significant difference in
testosterone, HbA1c, or relaxin was detected between groups.
HbA1c was within normal range in all individuals (range 4.9–
5.6%). FSH and LH were within normal range for menstrual
phases. LH was significantly higher in women tested within the
LP compared with women tested in FP or in the OC pill period.
LH and FSH concentrations were suppressed to below the detec-
tion levels (0.1 internal unit/l for both FSH and LH) in two OC
users in the pill period and one OC users in the off-pill period. All
blood data are shown in Table 2.
Tendon CSA
Tendon CSA (mm2) did not differ between the different phases
of the menstrual cycle and pill cycle (data not shown) in the NOC
or OC groups, respectively. Consequently, data from the different
phases within the OC groups and NOC groups was pooled in the
comparison between OC and NOC.
Tendon CSA adjusted for body weight (mm2/kg2/3) tended
to be significantly greater in the jumping leg compared with the
contralateral leg at the distal level of the patellar tendon (P 
0.09). Furthermore, there was a tendency toward a significant
interaction between training (jumping leg vs. contralateral leg)
and treatment (OC vs. NOC) (P  0.08). Post hoc analysis
revealed greater patellar tendon CSA (mm2/kg2/3) at the distal
tendon in the jumping leg compared with the contralateral leg
in OC users (P  0.05), but not in NOC users (P  0.98). No
difference in tendon CSA adjusted for body weight was ob-
served at the proximal and medial recording in the patellar
tendon between OC and NOC or between the legs (Fig. 1).
Mechanical Properties of the Patellar Tendon
No difference in mechanical properties of the patellar tendon
was observed between the two NOC groups tested in different
menstrual phases or between the OC groups tested in either the
pill period or in the off-pill period (data not shown). Therefore,
in the subsequent analyses for an effect of OC use and training
load on mechanical properties of the patellar tendon, data were
collapsed across the different time phases.
No difference in tendon biomechanical properties (group com-
mon force and individual common force) was observed between
Table 2. Blood parameters
NOC OC
Follicular Luteal Pill Pill	
n 7 8 8 7
Estradiol, nmol/l 0.14  0.02 0.40  0.07* 0.09  0.03 0.05  0.03
Progesterone, nmol/l 1.3 0.3 21.3  6.3* 2.9  2.0 1.8  0.5
FSH, int. unit/l 6.4  0.6 4.6  0.7 5.4  1.1 2.8  1.0
LH, int. unit/l 4.8  0.4 6.9  1.6† 5.6  2.0 2.0  0.4
Testosterone, nmol/l 1.0 0.1 1.3  0.2 1.4  0.2 1.3  0.2
IGF-I, g/l 389  25 348  25 317  21 228  16‡
HbA1c, % 5.4  0.1 5.3  0.1 5.2  0.1 5.2  0.1
Relaxin, ng/l 98  40 152  55 63  18 56  27
Values are means  SE; n, no. of subjects. FSH, follicle stimulating hormone; LH, lutenizing hormone; IGF-I, insulin-like growth factor I; int. unit, internal
unit (Hvidovre Hospital, Copenhagen); HbA1c, hemoglobin A1c. *Significant higher compared with the other groups (P 0.001). †Significant higher than pill	
(P  0.001) or follicular phase (P  0.002). ‡Significantly suppressed compared with the other groups.
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OC and NOC. Similarly, no significant interaction was observed
between treatment (OC vs. NOC) and training load (jumping leg
vs. contralateral leg) for any of the biomechanical tendon param-
eters examined (Tables 3 and 4). However, a tendency toward a
significant interaction between treatment and training load was
observed for stress (individual common force, N/mm2, P 0.06).
When comparing the tendon biomechanical properties be-
tween the legs, significant differences were observed for sev-
eral parameters. For the jumping leg at the maximal group
common force level (2,500 N), a significant reduced (11%)
strain (P  0.04), greater (15%) absolute stiffness (P  0.01),
and greater (14%) normalized stiffness (Young’s modulus,
P  0.02) were observed compared with the contralateral leg.
Furthermore, deformation tended to be lower (9%) in the
jumping leg compared with the contralateral leg (P  0.06).
When analyzing the data from the jumping leg at the same
individual common force level, tendon deformation was
smaller (11%) compared with that from the contralateral leg
(P 0.03). Furthermore, Young’s modulus tended to be higher
(12%) in the jumping leg compared with the contralateral leg
when analyzing the data at the same individual common force
level (P  0.11).
An inverse relationship between serum estradiol and tendon
stiffness was observed for all subjects (r  0.49, P  0.02).
Furthermore, correlations between serum estradiol and tendon
deformation (r  0.41, P  0.07) and strain (r  0.41, P 
0.07) also tended to be statistically significant (Fig. 2). Serum
estradiol did not correlate with any of the tendon biomechani-
cal data when the data from the OC groups were analyzed
separately, whereas serum estradiol within the NOC groups
correlated negatively with tendon stiffness (r  0.53, P 
0.04) and tended to correlate positively with tendon deforma-
tion (r  0.45, P  0.09) and tendon strain (r  0.49, P 
0.06), respectively. No tendon biomechanical parameters were
correlated with circulating testosterone or relaxin, but a posi-
tive correlation between serum progesterone and strain was
observed (r  0.52, P  0.04).
HbA1c correlated negatively with tendon deformation (r 
0.615, P  0.001), tendon strain (r  0.544, P  0.01),
and toe region strain (r  0.60, P  0.001). Furthermore,
HbA1c tended to correlate positively with the content of
cross-links (LyP, r  0.37, P  0.07). The latter finding was
even more pronounced when analyzing the data from the NOC
groups separately (HP, r  0.59, P  0.04; LyP, r  0.79,
P  0.001).
Tendon Structure
Tendon biopsies were obtained in the jumping leg in seven
OC users and in seven NOC users, whereas eight OC users and
six NOC users had a tendon biopsy taken in the contralateral
leg. No difference between phases in tendon fibril characteris-
tics, collagen content, or collagen cross-linkings was observed
when the two groups of OC users and two groups of NOC users
were compared separately. Therefore, all data from the OC
users and NOC users were merged in the subsequent compar-
isons between OC and NOC.
No difference between NOC and OC was observed in collagen
volume fraction (%) (P  0.73), fibril density (P  0.22), mean
fibril diameter (P 0.38), %fibrils with a diameter between 0 and
60 mm (P 0.24), between 61 and 90 mm (P 0.59), and above
90 mm (P  0.47) (Table 5). Likewise OC and NOC did not
differ with respect to tendon collagen content (P  0.25) and
cross-links (HP, P  0.48; LyP, P  0.69; and pentosidine P 
0.94, Fig. 3).
Fig. 1. Tendon cross-sectional area (CSA) (mm2/kg2/3) in the jumping leg and
contralateral leg in oral contraceptive users (OC; n  14) and nonusers of OC
(NOC; n  15). Values are means  SE. Two-way ANOVA (one-factor
repetition) results are as follows. A: proximal [treatment (OC vs. NOC), P 0.21,
training (jumping vs. contralateral leg), P  0.84, interaction (P  0.20)]. B: medial
(treatment P 0.22, training P 0.42, interaction P 0.27). C: distal (treatment
P  0.41, training P  0.09, interaction P  0.08). *P  0.05, significant effect
of training (jumping leg compared with the contralateral leg) in the OC users
(Student’s paired t-test).
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DISCUSSION
Effect of OC
In the present study, no significant influence of regular use
of OC on tendon morphology, major strength providing cross-
links of collagen, or tendon biomechanical properties in female
athletes was observed. The influence of OC on the risk of
overuse injuries and acute injuries is still debatable (9, 37, 55,
66, 76, 82). Moreover, the effect of exogenous female hor-
mones on tendon and ligament composition, tissue turnover,
and biomechanical properties is inconsistent (8, 26, 27, 51, 81).
In a previous study, we observed a lower collagen fractional
synthesis rate in the patellar tendon of young OC users than
NOC users, both at rest and in response to knee extensor
exercise (26, 27). This observation was related to OC reduce
bioavailability of IGF-I, which has a marked stimulating effect
on tendon collagen synthesis (24). In the present study, tendon
collagen content was not significantly reduced in OC users
(P 0.25), and the adaptation in tendon CSA to loading seems
to be more pronounced in OC users than NOC users. This
Table 3. Tendon biomechanical properties (group common force)
Jumping Contralateral
P Value
OC vs. NOC Training Interaction
Stress, MPa
NOC 30.0  0.8 29.4  0.8 0.35 0.49 0.17
OC 28.0  1.0 29.3  1.1
Deformation, mm
NOC 1.3  0.1 1.5  0.1 0.35 0.06 0.14
OC 1.5  0.1 1.6  0.1
Strain, %
NOC 2.8  0.2 3.2  0.2 0.41 0.04* 0.68
OC 3.1  0.2 3.4  0.3
Strain-toe region, %
NOC 1.3  0.1 1.5  0.1 0.42 0.20 0.52
OC 1.5  0.2 1.6  0.2
Stiffness, N/mm
NOC 3,768  293 3,243  233 0.57 0.01* 0.63
OC 3,477  338 3,062  237
Young’s modulus, GPa/%
NOC 2.2  0.2 1.8  0.1 0.46 0.02* 0.17
OC 1.9  0.1 1.8  0.2
Values are mean values of both legs  SE; n  14 (OC users), n  15 (NOC). The values are calculated based on the same common force (2,500 N) for
both groups to adjust for individual differences in muscle strength. Description of the test parameters is given in MATERIALS AND METHODS. The results based on
the jumping legs and contralateral legs are presented separately. P values show results from two-way ANOVA (one-factor repetition). *P  0.05, significant
effect of training (jumping leg vs contralateral leg).
Table 4. Tendon biomechanical properties (individual common force)
Jumping Contralateral
P Value
OC vs. NOC Training Interaction
Stress, MPa
NOC 46.1  2.9 43.9  2.8 0.69 0.53 0.06
OC 41.8  3.2 45.9  3.8
Deformation, mm
NOC 1.6  0.1 1.7  0.1 0.33 003* 0.83
OC 1.7  0.1 2.0  0.2
Strain, %
NOC 3.4  0.2 3.9  0.2 0.46 0.03 0.86
OC 3.7  0.2 4.1  0.3
Strain-toe region, %
NOC 1.4  0.2 1.6  0.2 0.15 0.29 0.54
OC 1.8  0.1 1.9  0.2
Stiffness, N/mm
NOC 4,423  339 4,013  363 0.43 0.37 0.68
OC 4,241  432 3,781  280
Young’s modulus, GPa/%
NOC 2.7  0.3 2.1  0.2 0.80 0.11 0.17
OC 2.4  0.2 2.4  0.3
Patellar force, N
NOC 3,643  220 3,799  245 0.75 0.18 0.55
OC 3,479  198 3,706  220
Values are means  SE; n  14 (OC users), n  15 (NOC). The values are calculated based on individual common force. Description of the test parameters
is given in MATERIALS AND METHODS. The results based on the jumping legs and contralateral legs are presented separately. P values show results from two-way
ANOVA (one-factor repetition). *P  0.05, significant effect of training (jumping leg vs. contralateral leg).
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suggests that OC reduces tendon collagen turnover. However,
this hypothesis awaits experimental verification.
Methods used in previous studies (8, 51, 60) to investigate
the association between use of OC and biomechanical proper-
ties of the connective tissue differ from the methods used in the
present study. Martineau et al. (51) observed reduced passive
anterior translation of the tibia measured by KT1000 in OC
users, but others have failed to reproduce these findings (60).
Bryant et al. (8) observed a reduced strain of the triceps surae
aponeurosis during maximal isometric plantar flexion in OC
users, measuring deformation of both the Achilles tendon and
the aponeourosis. Since the mechanical properties of the free
tendon and aponerosis is divergent (20, 47), it is difficult to
compare these data with the present data on the isolated effect
of isometric contraction on the tendon. Moreover, use of an
ultrasound head, which monitors the entire patellar tendon, as
in the present study, is considered superior when quantifying
deformation than single reference point, as in the study by
Bryant et al. (8).
Effect of Menstrual Cycle Phases and Estrogen
OC prevent the mid- and late-cycle surges of estrogen,
which have been associated with an enhanced knee laxity (16,
33, 62, 69, 70). Increased knee joint laxity influences landing
biomechanics and leads to increased knee joint loads during
athletic movements (59, 72) and enhanced risk of ACL injuries
(73, 80). Nevertheless, knowledge about direct effects of es-
trogen on the collagen structure and biomechanical properties
of the ACL is primarily based on in vitro studies or tests of
ACL from animals (41, 44, 68, 74, 83, 84), since the ACL is
not easily accessible in non-knee-injured subjects. Ligaments
and tendons have specific functions and may adapt differently
due to a potential differential composition of estrogen receptors
( and 
) (52). However, due to morphological/physiological
similarities between tendon and ligaments (collagen types,
%collagen of the extracellular matrix, and estrogen receptor
presence) (19, 32, 50), the effect of estrogen on the patellar
tendon may be transferred to the ACL and other knee ligaments
important for knee stability.
Differences in the mechanical properties of the patellar
tendon across menstrual phases were nonsignificant in the
present study. This may be due to different cyclic changes in
laxity among women, which reduce the possibility to detect a
difference between phases in a cross-sectional study (69, 71).
Still, circulating estradiol in NOC correlated with tendon
stiffness (r0.53, P 0.04), tendon deformation (r 0.45,
P 0.09), and strain (r 0.49, P 0.06) in the present study.
Although the generalizability between the properties of the
patellar tendon and the ACL can be questioned, our data on the
patellar tendon support the assumption that knee laxity is
increased if women are considerably exposed to estrogen (16,
62, 69, 70). However, the correlations presented showed that
difference in estrogen explained only approximately 20–28%
of the variations in the patellar tendon biomechanical proper-
ties. Based on this, it seems plausible to assume that the risk of
ACL is multifactorial, and several other risk factors must be
considered (35). The muscles serve as dynamic joint stabiliz-
ers, and the neuromuscular control of the knee flexors and
Table 5. Tendon fibril characteristics
NOC OC
P Value: OC
vs. NOC
Volume fraction, % 0.59  0.03 0.60 0.03 0.73
Density, fibril/m2 85  8 74  4 0.22
Mean fibril diameter, nm 87  4 92  4 0.38
Mean fibril area, nm2 7,325  574 8,250 684 0.28
%Fibrils
Diameter 0–60 nm 32  4 26  2 0.24
Diameter 61–90 nm 29  2 31  3 0.59
Diameter 90 nm 39  4 42  3 0.47
Values are means  SE; n  14 (OC users), n  13 (NOC). P values show
results from Student’s unpaired t-test.
Fig. 2. Correlations between serum estradiol in NOC and biomechanical
parameters. A: tendon stiffness. B: tendon deformation. C: tendon strain.
HbA1c, hemoglobin A1c.
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extensors influences the risk of an ACL rupture (85). It has
been suggested that female hormones may influence the neu-
romuscular joint control of the lower extremity (35, 72) and
muscle fatigability (64) and thereby the risk of injuries, but
these factors are not fully elucidated (12, 34, 40).
If high exposure to estrogen (average or peak level of estrogen)
alters ligaments and tendon composition and thereby their biome-
chanical properties by influencing fibroblast proliferation (44, 83,
84), collagen synthesis (41, 44, 83, 84), and/or collagen degrada-
tion (22, 36, 54, 65), the effect of estrogen is probably not acute,
but an accumulated effect over several cycles. In support, elderly
women who had used ERT for 17 yr were characterized by a
higher tendon collagen synthesis rate, changed tendon fibril mor-
phology, and a lower tendon stiffness compared with age-matched
postmenopausal controls (25).
Effect of Training Load
Tendon CSA adjusted for body weight was greater in the
jumping leg, which is an advantageous adaptation reducing
tissue stress during loading. Young’s modulus represents the
biomechanical quality of the tendon, which takes into account
differences in tendon CSA and differences in the absolute
loading of the tendon during the stiffness assessment. For both
groups, we observed a higher Young’s modulus in the patellar
tendon of the jumping leg, which has been exposed to a higher
load during the years of training compared with the contralat-
eral tendon. Furthermore, tendon stiffness was greater and
tendon deformation was lower during loading in the jumping
leg. Similarly, greater patellar tendon stiffness and CSA have
been observed in elite male badminton players and fencers in
the lead leg compared with the contralateral leg (14). Never-
theless, previous studies have indicated that the responsiveness
of tendon tissue to mechanical loading and the ability to adapt
to regular training was reduced in young women than in men
(30, 45, 53, 79). Actually, no change in tendon biomechanical
properties and CSA was observed in young women after 9 mo
of regular running training (30), and Westh et al. (79) observed no
difference in weight-normalized Achilles and patellar tendon CSA
between trained female runners (40 km/wk for 5 yr) and
untrained women, while CSA of the tendons was greater in
trained men compared with both female groups. The apparent
discrepancy between the present data and those reported pre-
viously (30, 79) may be owing to methodological differences
across study designs. Strength of the present design was that
the two legs within the same subject were compared instead of
comparing different groups of individuals. Still, based on the
present observations, we cannot exclude that women adapt less
sensitively to a given training stimuli compared with men.
HbA1c
HbA1c, a screening marker for abnormal glucose regulation,
was within normal range in all of the subjects. Nevertheless,
inverse relationships between HbA1c and tendon deformation
and strain were observed, which may be related to a higher
content of cross-links. If glucose regulation influences tendon
structure and biomechanical properties in healthy individual,
the effect may be even more pronounced in diabetic popula-
tions.
Limitations
Differences observed between the jumping leg and contralat-
eral leg underline the importance of taking into account not
only training status of the individuals, but also limb preference,
when comparing the biomechanical properties between dif-
ferent groups of subject. Training status (V˙ O2 max, physical
activity level, training volume, and frequency) did not differ
between OC and NOC. Still, we are aware that the cross-
sectional design includes some inherent limitations besides the
training status of the subjects. Furthermore, tendon mechanical
properties were only assessed at a single time point. These
Fig. 3. Patellar tendon concentration of col-
lagen (P  0.25; A), hydroxylysyl pyridino-
line (HP; P  0.48; B), lysyl pyridinoline
(LyP; P 0.69; C), and pentosidine (PENT;
P  0.94; D). Values are means  SE; OC
users, n  14; NOC, n  13. P values are
shown from Student’s unpaired t-test for test
of difference between groups.
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facts point to a small effect of OC or menstrual cycle on the
tendon biomechanical properties may have been overlooked
due to somewhat low statistical power.
Conclusion
No differences in patellar tendon structural composition,
collagen cross-linking, and biomechanical properties were ob-
served between users of OC and NOC. Serum estradiol was
inversely correlated to patellar tendon stiffness in NOC users.
If this finding on the patellar tendon is representative for the
effect of estrogen on other tendons and ligaments, the present
data support the findings in previous studies, linking high
exposure to estrogen in young women to increased knee laxity
and thus an elevated risk of an ACL injury.
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